<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211965</url>
  </required_header>
  <id_info>
    <org_study_id>Nabi-1363</org_study_id>
    <nct_id>NCT00211965</nct_id>
  </id_info>
  <brief_title>StaphVAX Immunogenicity and Safety in Orthopaedic Joint Surgery</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adult Patients Receiving an Orthopedic Prosthetic Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nabi Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Public Health England</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nabi Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Staphylococcus aureus (S. aureus) is the most common pathogen encountered in infections
      associated with orthopedic surgery. StaphVAX® is a bivalent S. aureus types 5 and 8 vaccine
      which contains the purified capsular polysaccharides that have been implicated as a major
      factor in the invasiveness of S. aureus. Immunoprophylaxis by vaccinating against S. aureus
      prior to surgery could provide sufficient antibody concentrations during surgery and the
      wound healing period so as to decrease the risk of S. aureus infection. This study aims to
      demonstrate the immunogenicity and safety of a single dose of StaphVAX in patients who are
      candidates for orthopedic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sero-type specific antibody concentrations</measure>
    <time_frame>6 weeks after study dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sero-type specific antibody concentrations</measure>
    <time_frame>various other time points after study dose, up to 26 wk</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>throughout 6 months observation after study dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Staphylococcal Infections</condition>
  <arm_group>
    <arm_group_label>vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate</intervention_name>
    <description>single IM dose of 200 mcg total conjugate</description>
    <arm_group_label>vaccine</arm_group_label>
    <other_name>StaphVAX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>single dose IM</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Candidate for knee or hip replacement

          -  Expectation of protocol compliance

          -  Negative pregnancy test, where appropriate

        Exclusion Criteria:

          -  Known S. aureus infection in the prior 3 months

          -  Infection in the prior 2 weeks

          -  Known HIV infection

          -  Immunomodulatory drugs

          -  Malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the
             cervix, or early prostate cancer)

          -  Hypersensitivity to components of StaphVAX
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matt Hohenboken, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nabi Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Royal Orthopaedic Hospital</name>
      <address>
        <city>Stanmore</city>
        <state>Middlesex</state>
        <zip>HA7 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>December 26, 2007</last_update_submitted>
  <last_update_submitted_qc>December 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Matt Hohenboken, MD, PhD, Executive Director Clinical &amp; Medical Affairs</name_title>
    <organization>Nabi Biopharmaceuticals</organization>
  </responsible_party>
  <keyword>Knee replacement surgery</keyword>
  <keyword>hip replacement surgery</keyword>
  <keyword>nosocomial infections</keyword>
  <keyword>Arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

